CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.

CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

Spire Wealth Management reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.2% during the 1st quarter, according to the company in its most recent 13F filing with the ...